1. |
Li W,Yanoff M, Jian B, et al. Altered mRNA levels of antioxidant enzymes inpre-apoptotic pericytes from human diabetic retinas. Cell Mol Biol(Noisy-le-grand) 1999; 45: 59-66.
|
2. |
Kaur C,Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions:basic concepts, clinical features and management. Prog Retin Eye Res 2008; 27:622-47.
|
3. |
JoussenAM, Poulaki V, Mitsiades N, et al. Suppression of Fas-FasL-induced endothelialcell apoptosis prevents diabetic blood-retinal barrier breakdown in a model ofstreptozotocin-induced diabetes. Faseb J 2003; 17:76-8.
|
4. |
Fadini GP,Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reducedin peripheral vascular complications of type 2 diabetes mellitus. J Am CollCardiol 2005; 45:1449-57.
|
5. |
CaballeroS, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired byhealthy, but not diabetic, endothelial progenitor cells. Diabetes 2007;56:960-7.
|
6. |
Li W,Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patientswith chronic and progressive diabetic macular edema. Ophthalmic Surg, LasersImaging 2010; 41:18-25.
|
7. |
Lipton SA.Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med2004; 350:2516-7.
|
8. |
WatanabeD, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor inproliferative diabetic retinopathy. N Engl J Med 2005; 353:782-92.
|
9. |
EarlyTreatment Diabetic Retinopathy Study Research Group. Grading diabeticretinopathy from stereoscopic color fundus photographs--an extension of themodified Airlie House classification: ETDRS report number 10. Ophthalmology1991; 98:786-806.
|
10 |
Busik JV,Tikhonenko M, Bhatwadekar A, et al. Diabetic retinopathy is associated withbone marrow neuropathy and a depressed peripheral clock. J Exp Med 2009; 206:2897-906.
|
11 |
BoilsonBA, Kiernan TJ, Harbuzariu A, et al. Circulating CD34+ cell subsetsin patients with coronary endothelial dysfunction. Nat Clin Pract CardiovascMed 2008; 5: 489-96.
|
12 |
Lee IG,Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenicfactors in the pathogenesis of diabetic retinopathy. Eye (Lond) 2006; 20:546-52.
|
13 |
Loomans CJ,de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novelconcept in the pathogenesis of vascular complications of type 1 diabetes.Diabetes 2004; 53:195-9.
|
14 |
Fadini GP,Coracina A, Baesso I, et al. Peripheral blood CD34+KDR+endothelial progenitor cells are determinants of subclinical atherosclerosis ina middle-aged general population. Stroke 2006; 37:2277-82.
|
15 |
Brunner S,Schernthaner GH, Satler M, et al. Correlation of different circulating endothelialprogenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci 2009; 50:392-8.
|
16 |
ImanishiT, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-inducedproliferation and network formation of endothelial progenitor cells. HypertensRes 2004; 27:101-8.
|
17 |
Wang CH,Verma S, Hsieh IC, et al. Enalapril increases ischemia-induced endothelial progenitorcell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol2006; 41:34-43.
|
18 |
WestenbrinkBD, Oeseburg H, Kleijn L, et al. Erythropoietin stimulates normal endothelialprogenitor cell-mediated endothelial turnover, but attributes to neovascularizationonly in the presence of local ischemia. Cardiovasc Drugs Ther 2008; 22:265-74.
|
19 |
Zhang J,Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects bothretinal vascular and neuronal cells in early diabetes. Invest Ophthalmol VisSci 2008; 49: 732-42.
|
20 |
Hern醤dezC, Fonollosa A, Garc韆-Ram韗ez M, et al. Erythropoietin is expressed in thehuman retina and it is highly elevated in the vitreous fluid of patients withdiabetic macular edema. Diabetes Care 2006; 29:2028-33.
|
21 |
AbuEl-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1alphaand the protein products of its target genes in diabetic fibrovascularepiretinal membranes. Br J Ophthalmol 2007; 91:822-6.
|
22 |
Zhang JF,Wu YL, Xu JY, et al. Pharmacokinetic and toxicity study of intravitrealerythropoietin in rabbits. Acta Pharmacol Sin 2008; 29:1383-90.
|
23 |
Lagr鑪e WA, Feltgen N, Bach M, et al. Feasibility of intravitrealerythropoietin injections in humans. Br J Ophthalmol 2009; 93:1667-71.
|
24 |
Yip HK,Tsai TH, Lin HS, et al. Effect of erythropoietin on level of circulatingendothelial progenitor cells and outcome in patients after acute ischemicstroke. Crit Care 2011; 15:R40.
|
25 |
Brines M,Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damagefrom the primary injury response. J Intern Med 2008; 264:405-32.
|
26 |
Fadini GP,Sartore S, Agostini C, et al. Significance of endothelial progenitor cells insubjects with diabetes. Diabetes Care 2007; 30:1305-13.
|